Sign up to save your podcasts
Or
Share Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
Guest: Sarah Sammons, MD
Guest: Carey Anders, MD, FASCO
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.
View all episodes
By ReachMDGuest: Sarah Sammons, MD
Guest: Carey Anders, MD, FASCO
The development and availability of HER2-directed therapies has dramatically improved outcomes for patients with metastatic breast cancer (MBC). Moreover, emerging data indicate that these therapies also improve outcomes for those with brain metastasis. In this educational series, expert faculty differentiate the available HER2-directed therapies for MBC, assess their efficacy in disease with brain metastasis, and review treatment selection and sequencing considerations for these agents.